Hypertrophic olivary degeneration secondary to a Guillain-Mollaret triangle lesion

1. Taratuto AL, Zuccaro G, Arias E, Mac Keith P, Muller C, Dominguez R. Whipple’s disease: an endless infection forty four years of disease and 15 years of brain involvement, report of a case. American Association of Neuropathologists, 86th Annual Meeting, Poster 124. J Neuropathol Exp Neurol. 2010; 69:553. 2. Vital-Durand D, Lecomte C, Cathebras P, Rousset H, Godeau P. Whipple disease. Clinical review of 52 cases. Medicine (Baltimore). 1997;76:170—84. 3. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple’s disease. Ann Neurol. 1996;40:561—8. 4. Gerard A, Sarrot-Reynauld F, Liozon E, Cathebras P, Besson G, Robin C, et al. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Medicine (Baltimore). 2002;81:443—57. 5. Ghigo E, Capo C, Aurouze M, Tung CH, Gorvel JP, Raoult D, et al. Survival of Tropheryma whipplei, the agent of Whipple’s disease, requires phagosome acidification. Infect Immun. 2002;70:1501—6. 6. Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother. 2004;48:747—52. 7. Marth T, Schneider T. Whipple disease. Curr Opin Gastroenterol. 2008;24:141—8. 8. Elsborg L, Gravgaard E, Jacobsen NO. Treatment of Whipple’s disease with sulphamethoxazole-trimethoprim. Acta Med Scand. 1975;198:141—3. 9. Fenollar F, Puechal X, Raoult D. Whipple’s disease. Medical Progress. N Engl J Med. 2007;356:55—66. 10. Freeman HJ. Tropheryma whipplei infection. World J Gastroenterol. 2009;15:2078—80. 11. Lagier JC, Fenollar F, Lepidi H, Raoult D. Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple’s disease. J Antimicrob Chemother. 2010;65: 2005—12.